Event

PSI Scientific Meeting: Adaptive Designs and their Application

Add to:

Sponsored by logo




Date: Thursday 13th October 2022
Time: 10:00-16:00 BST
Location: Face-to-Face (MRC Biostatistics Unit, Uni. of Cambridge) AND Online (Zoom)
Speakers: Sofia Villar (University of Cambridge), Olivier Collingon (GSK), Pantelis Vlachos (Cytel), Carl-Fredrik (Caffe) Burman (AstraZeneca), Frank Bretz (Novartis), Uli Burger (Roche) and Haiyan Zheng (MRC Biostatistics Unit).
Additional information: Please be advised that this is a hybrid event, meaning tickets will be available to attend either in-person, or online via Zoom. Please see the 'Registration' section below for more details.

Who is this event intended for? Anyone involved or interested in learning more about trial design. 
What is the benefit of attending? Learn about the current hot topics in adaptive designs and gain insight on how to use them in practice.

Cost

The following Member/Non-Member rates apply to both in-person and online attendance to this hybrid event.
Member rate = £40+VAT
Non-Member rate = £150*+VAT
*Please note: Non-Member rate includes membership for the rest of the 2022 calendar year, and the entirety of the 2023 calendar year.

Registration

PLEASE NOTE: You can register to attend this event live in-person, or live online. The cost is the same for both ticket types (Member/Non-Member price differences apply), but please be advised their is a set capacity for the number of delegates who can attend in-person. Once these tickets are sold-out, remaining tickets default to online-only. 
Please select carefully from the following options:

To register to attend this event FACE-TO-FACE, please click here.
To register to attend this event ONLINE, please click here.

Overview

Adaptive designs can offer more efficient trials for answering many questions of scientific interests. In this event we explore both cutting edge methodology for both the design and analysis of such designs. The speakers will offer insight into the use of such methods in the pharmaceutical setting, sharing their experiences from designing such trials. We will also hear personal views on adaptive designs. This event will be run in a hybrid format. We hope you will be able to join us in Cambridge and benefit from the opportunity to speak with others working in this area. For those that cannot attend there will be the option to attend online in the online one day meeting format that has been more familiar in recent times. 

Speakers

Speaker

Biography

Carledit
Carl-Fredrik Burman

 

Carl-Fredrik “Caffe” Burman has been working 27 years in the pharmaceutical industry. He is Senior Statistical Science Director in the methodology group, Statistical Innovation, within Data Science & AI at AstraZeneca R&D Gothenburg, Sweden. Most of his work is spent at the Trial Design & Modelling Centre, providing design support to project teams. Dr Burman is associated professor in Biostatistics at Chalmers University and associated editor for JBS. His research interests are mainly within design of clinical trials, decision analysis and multiple inference.

Oliveredit
Olivier Collignon

Dr Olivier Collignon is Associate Director at GSK in the United Kingdom where he leads a team of statisticians who contribute to the development of clinical trials for immune-inflammatory diseases. He holds a PhD in Applied Mathematics and is especially interested in basket, umbrella and platform trials, use of historical controls and clinical prediction models. He previously worked as a biostatistician in France and Luxembourg for more than 15 years. During his mission at the Luxembourg Institute of Health he was seconded at the European Medicines Agency in London for 4 years, where he gained regulatory experience and participated to the scientific evaluation of the design and results of clinical trials to obtain marketing authorization of new drugs in Europe.

Haiyanedit
Haiyan Zheng

Dr Haiyan Zheng is a CRUK Research Fellow in Statistical Methodology based in the MRC Biostatistics Unit. Her research is mainly focused on early phase clinical trials and adaptive methods for precision medicine. Haiyan currently leads a three-year research programme to develop statistical methods that (1) simultaneously evaluate treatment effects in multiple subgroups, and (2) allow for mid-course adaptations in master protocol trials.

Sofiaedit
Sofia Villar

Sofia is an MRC Investigator in the clinical trials methodology group, part of the Design and Analysis of Randomised Trials (DART) theme at the MRC Biostatistics Unit (BSU), University of Cambridge.

Sofia has a Ph. D. in Business Administration and Quantitative Methods at Universidad Carlos III de Madrid in July 2012, with a focus on Stochastic Dynamic Optimization. In 2013, she joined the BSU in Cambridge as part of a project on the design of multi-arm multi-stage clinical trials. In 2014, she was awarded the first ever Biometrika post-doctoral fellowship. Since the end of her fellowship she has been leading a team of statisticians at the BSU and at Papworth Hospital trials Unit. Sofia is currently working on a research programme that aims to improve clinical trial design through the development of innovative methods that lie in the intersection between optimisation, machine learning and statistics. A main focus of her research is to develop statistical methods for patient-centric adaptive clinical trials.

Pantelisedit
Pantelis Vlachos

Pantelis Vlachos is VP of Customer success in Cytel. He designs and implements clinical development programs and clinical trials, performs statistical analysis, and provides critical statistical input to support regulatory compliance. Pantelis has broad clinical research experience spanning early through late-stage clinical development and drug safety assessment in both large-scale pharmaceutical as well as academic settings. Prior to joining Cytel in 2013, Pantelis was a Principal Biostatistician at Merck Serono in Geneva, as well as a Professor of Statistics at Carnegie Mellon University for 12 years. He is a co-founder and former Managing Editor of Bayesian Analysis journal. He has also served on the editorial boards of various other journals, and online statistical data and software archives. Pantelis has contributed to the development of clinical development plans and provided statistical input to submission documents for regulatory authorities. His research interests lie in the area of adaptive designs, mainly from a Bayesian perspective, as well as hierarchical model testing and checking. He has applied his research in studies ranging from Phase I clinical pharmacology and dose escalation, Phase II dose finding, to Phase III studies in oncology, autoimmune disease, vaccines, and other. Pantelis contributes to software development and provides trainings for Cytel’s software products in Europe.

Frankedit
Frank Bretz

Frank Bretz is a Distinguished Quantitative Research Scientist at Novartis. He has supported the methodological development in various areas of drug development, including dose finding, estimands, multiple testing, and adaptive designs. He was a member of the ICH E9(R1) Expert Working Group on 'Estimands and sensitivity analysis in clinical trials' and currently serves on the ICH E20 Expert Working Group on 'Adaptive clinical trials'.

Uliedit
Uli Burger

Uli Burger has more than 30 years of industry experience at Roche in many therapeutic areas and all phases of drug development, and is currently global head of data and statistical sciences for Neuroscience there.

He has been involved in many statistical communities in organizing seminars and trainings including ROeS (Swiss Austrian region of the in international biometric society), EFSPI (European federation of statisticians in pharmaceutical industry), BBS (Basel Biometric Society) and DIA. Uli has been president of ROeS and EFSPI in the past, is the current president of the BBS and is also a member of the ICH E20 writing team.

 

Upcoming Events

Latest Jobs